Unlabelled: Alternative methods for assessing ULF spectral power using data from commercial Holter analysers were studied. Different heuristics for ULF calculation were compared with standard research software-based determination of ULF.
Setting: University Hospital.
Patients: 43 patients in NYHA classes I-IV heart failure and seven normals of similar ages.
Methods: SDNN, SDANN, ULF, VLF, LF, HF calculated from 24 h Holter monitoring using Oxford scanner software (method 1). ULF power also calculated by subtracting the sum of VLF. LF and HF powers obtained from the Holter scanner from the total variance (method 2) from 2 x ln(SDANN) (method 3), and by performing a standard, research-quality 24-h EFT analysis on the beat files (standard). Results of methods 1-3 were compared with standard using two-way ANOVA with repeated measures, regression analysis and a graphical technique.
Results: ULF calculated by method 1 correlated r=0.66 with standard but means differed substantially. In contrast, ULF calculated by method 2 correlated r=0.99 with standard with no significant differences between means. ULF calculated from SDANN (method 3) correlated r=0.983 with standard but means, while similar, were significantly lower (P=0.005).
Conclusion: ULF reported by commercial HOLTER software is not equivalent to ULF power derived from 24 h FFT analysis. ULF calculated by method 2 can be considered equivalent to the ULF derived by standard 24-h FFT. ULF estimated by method 3 offers direct ULF power estimation from a temporal measure of HRV and can be useful when spectral values are not available.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0167-5273(99)00085-6 | DOI Listing |
Dalton Trans
January 2025
Department of Computational Chemistry, Lund University, Chemical Centre, P. O. Box 124, SE-221 00 Lund, Sweden.
Particulate methane monooxygenase (pMMO) is the most efficient of the two groups of enzymes that can hydroxylate methane. The enzyme is membrane bound and therefore hard to study experimentally. For that reason, there is still no consensus regarding the location and nature of the active site.
View Article and Find Full Text PDFGraefes Arch Clin Exp Ophthalmol
November 2024
Eye Center Nymphenburger Höfe, Augenklinik Herzog Carl Theodor, Nymphenburger Str. 4, 80335, Munich, Germany.
Purpose: Vascular endothelial growth factor (VEGF) inhibition is the current and high-volume standard-of-care for patients with neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) with diabetic macular edema (DME). This study assessed the impact of non-persistence in anti-VEGF treatment using claims data from two German states.
Methods: This study identified adults with nAMD or DR/DME and incident anti-VEGF treatment (= index) in January 2015-June 2019 using the German AOK PLUS claims database (January 2014-June 2021, ~ 3.
Biomedicines
August 2024
Department of Neurology & Stroke, Eberhard-Karls University of Tübingen, 72076 Tübingen, Germany.
Background: The relationship between heart rate variability (HRV) changes potentially indicating autonomic dysregulation following spontaneous intracerebral hemorrhage (ICH) and functional outcome has not yet been fully elucidated. This study investigated the effects of HRV during the initial 96 h after admission on 90-day functional outcome in ICH patients.
Methods: We included patients with spontaneous ICH in a prospective cohort single-center study.
Phys Chem Chem Phys
July 2024
Biophysical Chemistry, Technical University Berlin, Strasse des 17. Juni 124, 10623 Berlin, Germany.
[FeFe]-hydrogenase is nature's most efficient proton reducing and H-oxidizing enzyme. However, biotechnological applications are hampered by the O sensitivity of this metalloenzyme, and the mechanism of aerobic deactivation is not well understood. Here, we explore the oxygen sensitivity of four mimics of the organometallic active site cofactor of [FeFe]-hydrogenase, [Fe(adt)(CO)(CN)] and [Fe(pdt)(CO)(CN)] ( = 1, 2) as well as the corresponding cofactor variants of the enzyme by means of infrared, Mössbauer, and NMR spectroscopy.
View Article and Find Full Text PDFPharmacoecon Open
September 2024
F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Background And Objective: Understanding the socioeconomic burden of multiple sclerosis (MS) is essential to inform policymakers and payers. Real-world studies have associated increasing costs and worsening quality of life (QoL) with disability progression. This study aims to further evaluate the impact of cognition, fatigue, upper and lower limb function (ULF, LLF) impairments, and disease progression per Expanded Disability Status Scale (EDSS) level, on costs and QoL.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!